The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Perrigo Company PLC

NYSE: PRGO
Last

(U.S.) $143.88

Today's change-0.23 -0.16%
Updated February 5 4:02 PM EST. Delayed by at least 15 minutes.
 

Perrigo Company PLC

NYSE: PRGO
Last

(U.S.) $143.88

Today's change-0.23 -0.16%
Updated February 5 4:02 PM EST. Delayed by at least 15 minutes.

Perrigo Company PLC down (U.S.)$0.23

Perrigo Company PLC closed lower Friday, dropping (U.S.)$0.23 or 0.16% to (U.S.)$143.88. Shares have lost 0.48% over the last five days, but are unchanged over the last year to date. This security has performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $142.76
  • Previous close(U.S.) $144.11
  • High(U.S.) $145.32
  • Low(U.S.) $142.28
  • Bid / Ask-- / --
  • YTD % change-0.57%
  • Volume1,480,281
  • Average volume (10-day)1,783,966
  • Average volume (1-month)1,635,345
  • Average volume (3-month)2,048,411
  • 52-week range(U.S.) $138.74 to (U.S.) $215.73
  • Beta0.29
  • Trailing P/E150.35×
  • P/E 1 year forward14.77×
  • Forward PEG1.05×
  • Indicated annual dividend(U.S.) $0.50
  • Dividend yield0.35%
  • Trailing EPS(U.S.) $0.96
Updated February 5 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+2.89%

Based on its net profit margin of 2.89%, Perrigo Company PLC is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 26, 201509/26/2015Jun 27, 201506/27/2015Mar 28, 201503/28/2015Dec 27, 201412/27/2014
Revenue1,3451,5321,0491,072
Total other revenue--------
Total revenue1,3451,5321,0491,072
Gross profit549628379384
Total cost of revenue796903670688
Total operating expense1,1561,306850897
Selling / general / administrative316339143144
Research & development42633553
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)21112
Other operating expenses, total--------
Operating income189226199175
Interest income (expense), net non-operating-44-47-43-31
Gain (loss) on sale of assets--------
Other--------
Income before tax132157-10385
Income after tax11357-9570
Income tax, total20101-815
Net income11357-9570
Total adjustments to net income--------
Net income before extra. items11357-9570
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items11357-9570
Inc. avail. to common incl. extra. items11357-9570
Diluted net income11357-9570
Dilution adjustment--------
Diluted weighted average shares147147141137
Diluted EPS excluding extraordinary itemsvalue per share0.770.39-0.670.51
Dividends per sharevalue per share0.130.130.130.11
Diluted normalized EPSvalue per share0.780.39-0.670.59